Tick-borne diseases are spreading into new parts of the United States at a pace that has caught public health officials off guard. Babesiosis, a potentially fatal parasitic infection once confined to ...

Melanie Stein, ND Clinical improvement in treatment-refractory MCAS with normal conventional biomarkers and profound oral ...

President Trump's doctor on Monday addressed what appeared to be red markings on the president's neck by saying that he was ...

Geoffrey Dow, PhD, CEO of 60 Degrees Pharmaceuticals, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the Company’s mission to combat infectious diseases with innovative ...

Serum samples were collected from 582 horses from 40 stud farms in the State of São Paulo and tick (Acari: Ixodidae) infestations were evaluated on them. Serum samples were subjected to the complement ...

A genetics‑guided small molecule called compound 6 gently turns down an overactive immune pathway (CARD9), offering a more precise, durable, and potentially safer treatment strategy for Crohn’s ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

A pilot study has found evidence of Bartonella and Babesia infection in almost half of 50 blood samples from patients suffering chronic fatigue syndrome, also called myalgic encephalomyelitis (ME).

Editor’s note: If you or someone you know is struggling with mental health, help is available. Dial or text 988 or visit 988lifeline.org for free and confidential support. Summer passed Valerie Zeko ...

• 60 Degrees Pharmaceuticals, Inc. (SXTP) shares rose 6.67% to $0.5899 in after-hours trading following positive study results. • A study revealed that 24% of patients with chronic fatigue tested ...

Add Yahoo as a preferred source to see more of our stories on Google. https://www.tipranks.com/news/the-fly/wells-sees-potential-upside-after-glaukos-idose-repeat ...

The FDA has approved its first at-home, nondrug therapy for depression, with a wearable brain stimulation headset developed by Flow Neuroscience. The agency issued a green light that covers the device ...